2023
DOI: 10.1016/j.esmoop.2023.101473
|View full text |Cite
|
Sign up to set email alerts
|

134P Impact of pre-operative MammaPrint/BluePrint use for final treatment decisions in patients with stage II/IIIa HR+/HER2- early-stage breast cancer eligible for neoadjuvant chemotherapy: The DETERMIND study

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles